Using Raman Spectroscopy to assess skin cancer tumors
Pilot Study of Raman Spectroscopic Imaging for Skin Cancer
Stony Brook University · NCT06384924
This study is testing a new imaging technique to see if it can help doctors better understand the size and spread of skin cancer tumors in patients with basal cell and squamous cell carcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stony Brook University (other) |
| Drugs / interventions | Radiation |
| Locations | 1 site (Stony Brook, New York) |
| Trial ID | NCT06384924 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of Raman Spectroscopy, a non-invasive imaging technique, in determining the size and spread of skin cancer tumors, specifically basal cell carcinoma and squamous cell carcinoma. By utilizing a handheld probe that emits laser light, the study seeks to identify the microscopic infiltration of cancerous tissues beyond what is visibly apparent. The findings could enhance the accuracy of skin brachytherapy treatments while minimizing radiation exposure to critical cosmetic areas. Advanced machine learning algorithms will be employed to analyze the data collected during the study.
Who should consider this trial
Good fit: Ideal candidates include individuals with histologically confirmed basal cell carcinoma or squamous cell carcinoma who are planning to receive brachytherapy treatment.
Not a fit: Patients with lesions near the eye, those unable to consent, or individuals in vulnerable populations may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more precise treatment planning for skin cancer, improving patient outcomes and reducing unnecessary radiation exposure.
How similar studies have performed: While Raman Spectroscopy has shown promise in other applications, this specific use for skin cancer assessment is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed skin cancer (either basal cell carcinoma or squamous cell carcinoma) * Participants must plan to receive brachytherapy treatment for the skin cancer at the study site. * Ability to provide consent to the study. Exclusion Criteria: * Patient belongs to a vulnerable population (Minors (under 18 years old), Adults unable to consent, prisoners). * Lesions on the eyelid or in close proximity to the eye * Pregnant women, or women of childbearing age who refuse pregnancy testing. * Patient has pacemaker.
Where this trial is running
Stony Brook, New York
- Stony Brook Hospital — Stony Brook, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Tiezhi Zhang — Stony Brook Cancer Center
- Study coordinator: Tiezhi Zhang
- Email: tiezhi.zhang@stonybrookmedicine.edu
- Phone: 631-444-3617
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma